Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
Kedrion-Kamada, Anti-COVID IG development update
Watch the interview given to LeFontiTV by the CEO of our partner Kamada
Rh&Life, first subject included in the study
Two hundred pregnant women to be enrolled over five countries
KIDCARES10, first patient enrolled in pediatric PI study
Thirty patients aged 2 to 17 years old to be enrolled over five European countries
Updates on anti-COVID treatment developed by Kamada and Kedrion
Top-line results announced from the phase 1/2 clinical trial in Israel
CARES10 clinical trial: last patient treated in the USA
Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients
First and Only US Pediatric human rabies Immune globulin Trial
Kedrion-Kamada Announce Study Met Its Primary Objective
First patient enrolled and treated in Kedrion’s CARES10 clinical study
Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients
Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”
International medical journal hosts review of contract plasma fractionation dynamics
FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
